The cardiovascular health activities are in response to the growing burden of these diseases due to the social, demographic, epidemiologic and health care transitions that have led to cardiovascular diseases being the number one cause of death in the country.
The activities are dedicated to:
| Sl No. | Title | Authors | Journal Name | Publication Year |
|---|---|---|---|---|
| 61 | Improving Evidence for Implementation of Guideline-Based Care in Low- and Middle-Income Countries | Granger CB, Xavier D | JAMA | 2018 |
| 62 | Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study | Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, Avezum A, Bai X, Chifamba J, Chow CK, Corsi DJ, Dagenais GR, Dans AL, Diaz R, Erbakan AN, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanas F, Lear SA, Li W, Liu J, Lopez-Jaramillo P, Mohan V, Monsef N, Mony PK, Puoane T, Rangarajan S, Rosengren A, Schutte AE, Sintaha M, Teo KK, Wielgosz A, Yeates K, Yin L, Yusoff K, Zatonska K, Yusuf S, McKee M | Lancet Glob Health | 2018 |
| 63 | Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery | Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, Chan MTV, Meyhoff CS, Xavier D, Sigamani A, Kumar PA, Mrkobrada M, Cook DJ, Tandon V, Alvarez-Garcia J, Villar JC, Painter TW, Landoni G, Fleischmann E, Lamy A, Whitlock R, Le Manach Y, Aphang-Lam M, Cata JP, Gao P, Terblanche NCS, Ramana PV, Jamieson KA, Bessissow A, Mendoza GR, Ramirez S, Diemunsch PA, Yusuf S, Devereaux PJ | Ann Intern Med | 2018 |
| 64 | Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE) | Duceppe E, Yusuf S, Tandon V, Rodseth R, Biccard BM, Xavier D, Szczeklik W, Meyhoff CS, Franzosi MG, Vincent J, Srinathan SK, Parlow J, Magloire P, Neary J, Rao M, Chaudhry NK, Mayosi B, de Nadal M, Popova E, Villar JC, Botto F, Berwanger O, Guyatt G, Eikelboom JW, Sessler DI, Kearon C, Pettit S, Connolly SJ, Sharma M, Bangdiwala SI, Devereaux PJ | Can J Cardiol | 2018 |
| 65 | Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes | Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM | J Am Coll Cardiol | 2018 |
| 66 | Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study | Ke C, Gupta R, Xavier D, Prabhakaran D, Mathur P, Kalkonde YV, Kolpak P, Suraweera W, Jha P; Million Death Study Collaborators. | Lancet Glob Health | 2018 |
| 67 | Potential of Probiotics in Hypercholesterolemia: A Review of In Vitro and In Vivo Findings | Sharma S, Puri S, Kurpad AV | Altern Ther Health Med | 2018 |
| 68 | Hypertension: The most important non communicable disease risk factor in India | Gupta R, Xavier D | Indian Heart Journal | 2018 |
| 69 | Low quality cardiovascular care is important coronary risk factor in India | Gupta R, Khedar RS, Gaur K, Xavier D | Indian Heart Journal | 2018 |
| 70 | Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial | Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, Xavier D, Szczeklik W, Meyhoff CS, et al; MANAGE Investigators | Lancet | 2018 |
| 71 | First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study | Bosch J, Lonn E, Zhu J, Pais P, Xavier D, Dans A, Diaz R, Hart R, Yusuf S | Stroke | 2018 |
| 72 | Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study | Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupta R, Lear S, Wentzel-Viljoen E, Avezum A, Lopez-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Oguz A, Lanas F, Rozanska D, Bostrom KB, Yusoff K, Tsolkile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deeraili A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S; Prospective Urban Rural Epidemiology (PURE) study investigators. | Lancet | 2018 |
| 73 | Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study | Mente A, O'Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, Lear S, Ah STL, Wei L, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Mony P, Szuba A, Iqbal R, Yusuf R, Mohammadifard N, Khatib R, Yusoff K, Ismail N, Gulec S, Rosengren A, Yusufali A, Kruger L, Tsolekile LP, Chifamba J, Dans A, Alhabib KF, Yeates K, Teo K, Yusuf S | Lancet | 2018 |
| 74 | The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct | Joseph P, Pais P, Dans AL, Bosch J, Xavier D, Lopez-Jaramillo P, Yusoff K, Santoso A, Talukder S, Gamra H, Yeates K, Lopez PC, Tyrwhitt J, Gao P, Teo K, Yusuf S; TIPS-3 Investigators | Am Heart J | 2018 |
| 75 | Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial | Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. | J Am Coll Cardiol | 2018 |